Shankar Siva1, Roshini Thomas2, Jason Callahan3, Nicholas Hardcastle4, Daniel Pham2, Tomas Kron5, Rodney J Hicks6, Michael P MacManus1, David L Ball1, Michael S Hofman6. 1. Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia; Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Australia. 2. Department of Radiotherapy Services, Peter MacCallum Cancer Centre, Australia. 3. Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Australia. 4. Department of Physical Sciences, Peter MacCallum Cancer Centre, Australia. 5. Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia; Department of Physical Sciences, Peter MacCallum Cancer Centre, Australia. 6. Sir Peter MacCallum Department of Oncology, University of Melbourne, Australia; Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Australia.
Abstract
BACKGROUND AND PURPOSE: To assess the utility of functional lung avoidance using IMRT informed by four-dimensional (4D) ventilation/perfusion (V/Q) PET/CT. MATERIALS AND METHODS: In a prospective clinical trial, patients with non-small cell lung cancer (NSCLC) underwent 4D-V/Q PET/CT scanning before 60Gy of definitive chemoradiation. Both "highly perfused" (HPLung) and "highly ventilated" (HVLung) lung volumes were delineated using a 70th centile SUV threshold, and a "ventilated lung volume" (VLung) was created using a 50th centile SUV threshold. For each patient four IMRT plans were created, optimised to the anatomical lung, HPLung, HVLung and VLung volumes, respectively. Improvements in functional dose volumetrics when optimising to functional volumes were assessed using mean lung dose (MLD), V5, V10, V20, V30, V40, V50 and V60 parameters. RESULTS: The study cohort consisted of 20 patients with 80 IMRT plans. Plans optimised to HPLung resulted in a significant reduction of functional MLD by a mean of 13.0% (1.7Gy), p=0.02. Functional V5, V10 and V20 were improved by 13.2%, 7.3% and 3.8% respectively (p-values<0.04). There was no significant sparing of dose to functional lung when adapting to VLung or HVLung. Plan quality was highly consistent with a mean PTV D95 and D5 ranging from 60.8Gy to 61.0Gy and 63.4Gy to 64.5Gy, respectively, and mean conformity and heterogeneity index ranging from 1.11 to 1.17 and 0.94 to 0.95, respectively. CONCLUSION: IMRT plans adapted to perfused but not ventilated lung on 4D-V/Q PET/CT allowed for reduced dose to functional lung whilst maintaining consistent plan quality.
BACKGROUND AND PURPOSE: To assess the utility of functional lung avoidance using IMRT informed by four-dimensional (4D) ventilation/perfusion (V/Q) PET/CT. MATERIALS AND METHODS: In a prospective clinical trial, patients with non-small cell lung cancer (NSCLC) underwent 4D-V/Q PET/CT scanning before 60Gy of definitive chemoradiation. Both "highly perfused" (HPLung) and "highly ventilated" (HVLung) lung volumes were delineated using a 70th centile SUV threshold, and a "ventilated lung volume" (VLung) was created using a 50th centile SUV threshold. For each patient four IMRT plans were created, optimised to the anatomical lung, HPLung, HVLung and VLung volumes, respectively. Improvements in functional dose volumetrics when optimising to functional volumes were assessed using mean lung dose (MLD), V5, V10, V20, V30, V40, V50 and V60 parameters. RESULTS: The study cohort consisted of 20 patients with 80 IMRT plans. Plans optimised to HPLung resulted in a significant reduction of functional MLD by a mean of 13.0% (1.7Gy), p=0.02. Functional V5, V10 and V20 were improved by 13.2%, 7.3% and 3.8% respectively (p-values<0.04). There was no significant sparing of dose to functional lung when adapting to VLung or HVLung. Plan quality was highly consistent with a mean PTV D95 and D5 ranging from 60.8Gy to 61.0Gy and 63.4Gy to 64.5Gy, respectively, and mean conformity and heterogeneity index ranging from 1.11 to 1.17 and 0.94 to 0.95, respectively. CONCLUSION: IMRT plans adapted to perfused but not ventilated lung on 4D-V/Q PET/CT allowed for reduced dose to functional lung whilst maintaining consistent plan quality.
Authors: Faegheh S Mounessi; Jörg Eckardt; Arne Holstein; Santiago Ewig; Stefan Könemann Journal: Strahlenther Onkol Date: 2019-10-02 Impact factor: 3.621
Authors: Pierre-Yves Le Roux; Amir Iravani; Jason Callahan; Kate Burbury; Peter Eu; Daniel P Steinfort; Eddie Lau; Beverly Woon; Pierre-Yves Salaun; Rodney J Hicks; Michael S Hofman Journal: Eur J Nucl Med Mol Imaging Date: 2019-05-01 Impact factor: 9.236
Authors: Eunsin Lee; Jing Zeng; Robert S Miyaoka; Jatinder Saini; Paul E Kinahan; George A Sandison; Tony Wong; Hubert J Vesselle; Ramesh Rengan; Stephen R Bowen Journal: Med Phys Date: 2017-06-01 Impact factor: 4.071
Authors: Yevgeniy Vinogradskiy; Chad G Rusthoven; Leah Schubert; Bernard Jones; Austin Faught; Richard Castillo; Edward Castillo; Laurie E Gaspar; Jennifer Kwak; Timothy Waxweiler; Michele Dougherty; Dexiang Gao; Craig Stevens; Moyed Miften; Brian Kavanagh; Thomas Guerrero; Inga Grills Journal: Int J Radiat Oncol Biol Phys Date: 2018-10-18 Impact factor: 7.038
Authors: Wei Shao; Taylor J Patton; Sarah E Gerard; Yue Pan; Joseph M Reinhardt; Oguz C Durumeric; John E Bayouth; Gary E Christensen Journal: IEEE Trans Med Imaging Date: 2019-12-30 Impact factor: 10.048